| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 15th December 2020 | Davis Jerel | 9,497 | Other acquisition or disposition | $0.00 | |
| 15th December 2020 | Davis Jerel | 285,217 | Other acquisition or disposition | $0.00 | |
| 15th December 2020 | Davis Jerel | 21,707 | Other acquisition or disposition | $0.00 | |
| 15th December 2020 | Davis Jerel | 8,579 | Other acquisition or disposition | $0.00 | |
| 9th December 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.08 | $26,150.00 |
| 8th December 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.24 | $26,483.40 |
| 23rd November 2020 | Srinivas Akkaraju | 500,000 | Grant/award etc. | $10.00 | $5,000,000.00 |
| 11th November 2020 | Eric Dobmeier | 2,500 | Open or private purchase | $13.75 | $34,375.00 |
| 10th November 2020 | Eric Dobmeier | 2,000 | Open or private purchase | $13.86 | $27,720.00 |
| 5th October 2020 | Eric Dobmeier | 46,337 | Grant/award etc. | $0.00 |
Aduro Bio Tech
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD. The company's platforms stimulate and/or regulate innate and adaptive immune responses.
Ticker: ADRO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1435049
Employees: 96
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $2 M for the period Apr 2020 to Jun 2020 in the context of all up
Restructuring Charges of $6 M for the period Jan 2020 to Jun 2020 in the context of all up
Restructuring Charges of $367 Th for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $400 Th for the period Apr 2019 to Jun 2019 in the context of all up
Restructuring Charges of $3 M for the period Jan 2019 to Jun 2019 in the context of all up
Restructuring Charges of $3 M for the period Jan 2019 to Jun 2019 in the context of all up
Fundamentals
Cash at Carrying Value: $71 M (0%)
Marketable Securities, Current: $100 M (-35%)
Assets, Current: $181 M (-16%)
Property, Plant and Equipment, Net: $22 M (0%)
Assets: $265 M (-8%)
Accounts Payable, Current: $1 M (223%)
Liabilities, Current: $20 M (-6%)
Other Liabilities, Noncurrent: $753 Th (-19%)
Liabilities: $219 M (-3%)
Common Stock, Value, Issued: $8 Th (0%)
Common Stock, Shares, Issued: $81 M (0%)
Additional Paid in Capital, Common Stock: $557 M (0%)
Retained Earnings (Accumulated Deficit): $511 M (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $439 Th (6%)
Stockholders' Equity (Parent): $47 M (0%)
Liabilities and Equity: $265 M (-8%)
Revenue: $6 M (-71%)
Research and Development: $11 M (-58%)
General and Administrative Expenses: $9 M (-45%)
Restructuring Charges: $2 M (0%)
Operating Income/Loss: $17 M (-45%)
Other Income, net: $385 Th (-70%)
Provision for income taxes: $6 M (0%)
News
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
